Gongwin Biopharm’s U.S. Subsidiary to Receive $50 Million Investment from Fund A for Clinical Trials in the U.S.

Gongwin-KY announced on the evening of July 10 that its subsidiary, Gongwin Biopharm, received a letter of intent (LOI) from Fund A on July 9. Fund A plans to participate in the establishment of Gongwin’s U.S. subsidiary and intends to invest up to $50 million USD (approximately NT$1.462 billion), representing about half of the Series A fundraising target of $100 million USD. This round of fundraising is expected to release approximately 20% to 25% of the equity.